Company intelligence / Profile preview
Tarian Pharma
Grasse, Provence-Alpes-Côte d’Azur, Francetarianpharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Tarian Pharma is developing innovative topical small molecule drugs for the prevention and treatment of severe skin toxicities in cancer patients. Their lead candidate, TAR-0520, a novel topical formulation of brimonidine tartrate targeting the α2 adrenergic receptor, is advancing through Phase 1 and Phase 2 clinical trials for multiple oncodermatology supportive care indications. Preclinical and early clinical data support its safety profile and efficacy in reducing cutaneous adverse effects from cancer therapies.
- Therapeutic areas
- DermatologyOncology
- Modalities
- Small moleculeTopical drug formulationVasoconstrictor therapy (Brimonidine-based)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Bpifrancei-LAB Competition/BPI FrancePaca‑Est Incubator
Beyond the preview
Go deeper on Tarian Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tarian Pharma.